Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Obesity, diet, & lifestyle interventions


Browse the latest news, expert commentary, and educational content on obesity and lifestyle interventions.


Highlights

07-03-2023 | Type 2 diabetes | News

‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

02-14-2023 | Obesity | News

Obesity as prevalent in type 1 diabetes as general US population

There is a “substantial” burden of overweight and obesity among people with type 1 diabetes, say US researchers who found rates to be in line with that of the general population.

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

More on obesity & lifestyle interventions

10-24-2023 | Type 2 diabetes | News

Prediabetes remission with lifestyle intervention reduces type 2 diabetes risk

09-25-2023 | Gestational diabetes | News

Gestational diabetes independently linked to increased future mortality risk

09-15-2023 | Type 2 diabetes | News

Young-onset type 2 diabetes diagnosis linked to shortened life expectancy

07-28-2023 | Type 2 diabetes | News

Better QoL after gastric bypass than sleeve gastrectomy for people with type 2 diabetes

DiRECT: Type 2 diabetes remission through weight management

Primary findings, 2-year outcomes and translating this landmark trial into practice

07-14-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

07-03-2023 | Type 2 diabetes | News

‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

06-05-2023 | Prediabetes | News

Caloric restriction outperforms liraglutide for weight loss in prediabetes

05-04-2023 | Diet | News

DiRECT extension shows potential for persistent type 2 diabetes remission

05-04-2023 | Diet | News

More exercise may be better for beta-cell function in type 2 diabetes

04-25-2023 | Diet | News

Time-restricted fasting improves postprandial glucose tolerance

02-14-2023 | Obesity | News

Obesity as prevalent in type 1 diabetes as general US population

01-17-2023 | Lifestyle interventions | News

Healthy lifestyle wards off type 2 diabetes microvascular complications
Image Credits